Sunshine Biopharma Incorporated (SBFM)

Over the past six months, Sunshine Biopharma's stock has been impacted by several events. The company reported fiscal 2025 revenue of $36.3 million, a 4.1% increase, with a net loss of $5.98 million, and Q4 2025 EPS missed analysts' expectations. Health Canada authorized the marketing of Domperidone, and the company launched Doxycycline and Pravastatin in October 2025. Director Natan David received 100,000 SBFM shares in a stock award in April 2026. Shareholders have experienced substantial dilution, with total shares outstanding growing by 34.9%. The company's share price has been highly volatile, and as of May 4, 2026, the stock price was $1.09 per share, a 14.17% decline from May 5, 2025.

Information directly pertaining to the demand seasonality for Sunshine Biopharma's specific pharmaceutical products and services is not explicitly available. However, historical stock data suggests a potential seasonal pattern, with a "Buy Date of November 21 and a Sell Date of February 11" showing a geometric average return of 68.67% above the S&P 500 Total Return Index over the past five years. September has historically offered the highest probability of positive returns for SBFM stock at 50.00%, while May may not be an ideal month for investment with a 40.00% probability of positive return.

Sunshine Biopharma, Inc. (SBFM) is a pharmaceutical company focused on researching, developing, and commercializing life-saving medicines, particularly in oncology and antivirals, with a presence in generic prescription drugs and OTC products. The company operates in the Healthcare sector, specifically in the Biotechnology & Drugs and Drug Manufacturers - Specialty & Generic industries, integrating a commercial generics and biosimilars platform with an internal proprietary drug development program. Key products include SBFM-PL4 for SARS coronavirus infections, Adva-27a for pancreatic cancer, K1.1 mRNA for liver cancer, a catalog of generic prescription drugs marketed through Nora Pharma Inc., and OTC supplements sold through Sunshine Biopharma Canada Inc.

Sunshine Biopharma operates in the United States and Canada, with its headquarters in Fort Lauderdale, Florida. The commercialization of generic prescription drugs and OTC products is primarily conducted in Canada through its subsidiaries, Nora Pharma Inc. and Sunshine Biopharma Canada Inc.

Sunshine Biopharma's brand reputation has been positively influenced by regulatory successes, such as Health Canada's approval for Domperidone, and new product launches, including Doxycycline and Pravastatin. The company's research and development progress in oncology and antivirals also contributes positively to its reputation. Increased revenue for fiscal 2025 indicates growth in its commercial operations.

Sunshine Biopharma, Inc. has a diverse ownership structure. Approximately 41.98% of its stock is owned by institutional investors, individual insiders own 83.66%, and the general public owns 13.99%. Major institutional owners include Citadel Advisors Llc, Virtu Financial LLC, and Morgan Stanley. Key individual insiders include Malek Chamoun (75.42%), Camille Sebaaly (3.56%), Steve N. Slilaty (2.65%), and David Natan (2.04%).